UAMY UNITED STATES ANTIMONY CORP Insider Trading

Director Jon R Marinelli buys 12.5K shares of UAMY at $7.45; stock down 60.5% from $19.71 high, company deeply unprofitable with -$11.3M net income

Jon R Marinelli, a director, established an initial 12,500-share position in UNITED STATES ANTIMONY CORP at $7.45 on 2026-06-15, representing $93,125.00 in capital deployment. The purchase occurs against a backdrop of significant headwinds: the stock trades at $7.78, down -60.5% from its 52-week high of $19.71, and has declined -14.6% over the past 90 days. Despite these depressed conditions, the company's financial fundamentals are severely strained—it reported a net loss of $11,294,490.00 in its most recent full fiscal year, placing it in unprofitable territory, though it showed robust revenue growth of +162.8% year-over-year and maintains a $1.2B market capitalization. The director's initiation of a position in a deeply underwater stock with substantial losses raises questions about directional confidence versus the material financial deterioration evident in recent results.

UAMY Chairman/CEO Gary Evans buys 100,000 shares ($613.2K) at $6.13; stock up 36.3% in 30d, but his prior UAMY purchase showed -10.2% 90d return

Gary Evans, Chairman & CEO of United States Antimony Corp, purchased 100,000 shares (100.0K shares) at $6.13 on 2025-09-26, bringing his total holdings to 2,378,818 shares (2.38M shares) and increasing his stake by 4.4%. The stock has gained 36.3% over the past 30 days and 191.1% over 90 days, though it remains 15.1% below its 52-week high of $7.30. However, Evans's track record on this specific ticker is cautionary: his prior buy at UAMY on 2024-12-10 showed a 90-day return of -10.2%, and across all his open-market purchases, his 90-day win rate stands at 0.00%. The company reported strong annual revenue growth of +71.8% and a recent quarterly revenue of $10,525,123.00 ($10.5M), but it remains unprofitable, with full-year net income in negative territory. This purchase may reflect conviction in the company's turnaround trajectory, yet the recent momentum in the stock price and the executive's lack of successful 90-day timing outcomes on prior buys warrant close monitoring of whether this price appreciation proves sustainable.

Director Michael A McManus Jr bought 70,000 shares of UAMY at $1.46 on 2024-12-10, raising holdings to 338,333 shares (+26.1%)

McManus executed a substantial $102,060.00 purchase, increasing his position by 26.1% to 338,333 shares. This marks his second open-market buy at UAMY within four weeks (prior purchase on 2024-11-18), suggesting sustained accumulation at depressed valuations—the stock is trading at $1.50, down 21.0% from its 52-week high of $1.90. Across his broader portfolio, McManus's track record shows 2 prior buys averaging +85.5% 30-day returns and +61.9% 90-day returns with a 100% win rate; his prior UAMY buy on 2024-08-14 posted +85.5% 30-day and +61.9% 90-day returns, with one of one prior buys well-timed. However, the timing context matters: UAMY's recent momentum (+119.2% 30-day, +130.8% 90-day) coincides with the company's weak fundamentals—revenue declined 21.3% year-over-year, the latest quarter posted a $727,509.00 net loss, and the company remains unprofitable on a full-year basis. The concentration of purchases during price recovery in an unprofitable entity with contracting revenue warrants careful attention to underlying catalysts driving this accumulation.

UAMY Chairman & CEO Evans purchases 200,000 shares ($289.4K) at $1.45; holdings increase 15.1% despite company losses

Gary C. Evans, Chairman & CEO of United States Antimony Corp, executed a $289,400 purchase of 200,000 shares at $1.45 per share, increasing his holdings by 15.1% to 1,528,818 shares post-transaction. This substantial equity stake expansion occurs in a context of operational headwinds: the company posted a net loss of $-727,509 over its latest quarter and negative full-year net income, with annual revenue contracting 21.3% year-over-year. The timing is notable given recent price recovery—the stock has rallied 119.2% over the past 30 days and 130.8% over 90 days from severely depressed levels (52-week low of $0.21)—suggesting the CEO's accumulation decision was made after significant appreciation from trough. The purchase price of $1.45 sits at a 3.3% discount to current market price of $1.50 but remains 23.7% below the 52-week high of $1.90, leaving material gap between execution and prior peak valuations.

UAMY Director McManus buys 50,000 shares at $0.56; prior trade at ticker achieved 90d +61.9% return

Director Michael A McManus Jr purchased 50,000 shares of UNITED STATES ANTIMONY CORP at $0.56 on 2024-11-18, increasing his holdings by 22.9% to 268,333 shares. This marks his second open-market purchase at this ticker; his prior buy on 2024-08-14 delivered a 90-day return of +61.9%, demonstrating a pattern of well-timed accumulation at this name. However, the company faces material headwinds: revenue contracted 21.3% year-over-year to $2.4M in the latest quarter, net income was -$727.5K, and the company remains unprofitable on a full-year basis. The current stock price of $0.69 is 11.5% below the 52-week high, and the 90-day price change is -3.6%, suggesting the insider is purchasing into recent weakness. The combination of repeated director buying against deteriorating fundamentals warrants attention to whether this reflects contrarian conviction or whether deteriorating operations may pressure the stock further.

CFO of UAMY buys 5,000 shares at $0.69; company saw -21.3% annual revenue decline and full-year net loss

Richard Isaak, SVP and Chief Financial Officer of United States Antimony Corp, purchased 5,000 shares at $0.69 on 2024-09-09, increasing his holdings to 71,667 shares. The timing coincides with a significant rally: the stock has risen 69.0% over the prior 30 days and 66.1% over the prior 90 days from a 52-week low of $0.21. However, the company's fundamentals remain challenged: annual revenue declined -21.3% year-over-year to $2.8M in the latest quarter, and the firm was unprofitable over its most recent full fiscal year. The CFO's personal purchase represents a small-scale addition (7.5% increase in his holdings) at the elevated end of the 52-week range ($0.69 vs $0.73 high), occurring after the stock has already appreciated significantly off lows.

Controller Hubert Rachel purchases 7,500 shares at blended $0.45 in UAMY amid 30-day +80.1% rally and full-year unprofitability.

Hubert Rachel, the Controller at United States Antimony Corp, executed 2 separate purchases totaling 7,500 shares for $3,372.00 on 2024-08-15, establishing an initial position at a blended average price of $0.45. This acquisition occurs at the top of the company's 52-week range ($0.21–$0.56), with the stock having rallied 80.1% over the prior 30 days and 112.1% over 90 days. The company reported negative full-year net income despite positive quarterly revenue of $2,813,780, indicating ongoing profitability challenges; annual revenue growth stands at -21.3%, signaling a contracting business. As a Controller—a financial officer responsible for accounting and controls—Rachel's purchase at peak valuation following a steep rally warrants examination of whether this reflects confidence in a turnaround or is independent of discretionary timing factors.

UAMY Director MCMANUS MICHAEL A JR purchased 135,000 shares at $0.38 on 2024-08-14; holdings increased 162.0% to 218,333 shares

MCMANUS MICHAEL A JR, a director, acquired 135,000 shares at $0.38 per share on 2024-08-14, increasing his holdings from 83,333 shares to 218,333 shares—a 162.0% expansion of his position. The purchase occurred at a price 20.8% below the current $0.48 price and as the stock rallied +91.6% over 90 days. The acquisition is notable given the company's challenging fundamentals: full-year net income was negative, revenue declined 21.3% year-over-year, and the market cap is $52.1M against quarterly revenue of $2.8M. The director's substantial share accumulation at a price materially below current levels provides a datapoint on insider positioning, though the company's unprofitable status and annual revenue contraction warrant scrutiny of the underlying business trajectory.